For analysis, patients were divided into two groups: patients of group I, for whom a heterozygous rare variant of STAT3 has been identified (n = 27), and patients of group II, with clinical features similar to those of patients with AD STAT3 deficiency, but without any genetic diagnosis (n = 76). This evidence concerns the gene STAT3 and Alzheimer disease.